All In Biotech

Drug Trial Radar · NCT03036813

Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease

Last checked: Nov 20, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 449 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

449

Actual

Start

Dec 2016

Primary completion

Oct 8, 2019

Study completion Oct 8, 2019

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 30, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease

Conditions

  • Sickle Cell Disease

Interventions

  • voxelotorDrug

  • PlaceboOther

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Increase in Hb >1 g/dL From Baseline to Week 24Time frame: Baseline to Week 24

Locations

62 sites in 12 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Oakland, California

  • Site not named

    Miami, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Baton Rouge, Louisiana

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Bethesda, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Newark, New Jersey

  • Site not named

    New York, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Durham, North Carolina

  • Site not named

    Greenville, North Carolina

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Memphis, Tennessee

  • Site not named

    Nashville, Tennessee

  • Site not named

    Houston, Texas

  • Site not named

    Richmond, Virginia

  • Site not named

    Toronto, Canada

  • Site not named

    Alexandria, Egypt

  • Site not named

    Cairo, Egypt

  • Site not named

    Cairo, Egypt

  • Site not named

    Zagazig, Egypt

  • Site not named

    Créteil, France

  • Site not named

    Paris, France

  • Site not named

    Paris, France

  • Site not named

    Padova, Italy

  • Site not named

    Verona, Italy

  • Site not named

    Monza, Milano, Italy

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.